Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris

Tal, Abdul Kader El; Posner, Marshall R.; Spigelman, Zachary; Ahmed, A. Razzaque

doi:10.1016/j.jaad.2006.05.009

Cited by 62 publications

(37 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…B cell depletion in humans using CD20 mAb (rituximab) can be effective in treating patients with various autoimmune disorders such as rheumatoid arthritis and lupus (18)(19)(20)(21)(22). CD20 is a B cellspecific molecule that is first expressed on the cell surface during the pre-B to immature B cell transition but is lost upon plasma cell differentiation (23,24).…”

Section: Introductionmentioning

confidence: 99%

Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression

Matsushita

Yanaba²,

Bouaziz³

et al. 2008

J. Clin. Invest.

627

905

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression

Matsushita

Yanaba²,

Bouaziz³

et al. 2008

J. Clin. Invest.

627

905

View full text Add to dashboard Cite

“…Various systemic immune modulating agents have been reported as effective adjunctive therapy including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, cyclosporine, and intravenous immune globulin (IVIG) [2,11]. Rituximab, a monoclonal antibody directed against the B-cell surface marker CD20, is also used in the treatment of pemphigus [12]. Our data reveals that dermatologists prescribe prednisone to almost half of patients with autoimmune bullous disorders.…”

Section: Discussionmentioning

confidence: 87%

Characterizing the Treatment of Autoimmune Bullous Disorders from 1993 through 2010: a NAMCS Study

W¹

2014

J Clin Investig Dermatol

View full text Add to dashboard Cite

Autoimmune blistering diseases, though uncommon, are associated with considerable morbidity. There is no established therapeutic ladder for the treatment of blistering disorders. Data from the National Ambulatory Medical Care survey from 1993 to 2010 was analyzed to determine the number of visits for blistering diseases, patient demographics, the specialty of treating physicians, and the most frequently prescribed treatments. Patients with autoimmune blistering disorders were primarily elderly, female, and non-Hispanic white. The majority of patients were managed by dermatologists. There has been no significant change in the number of patients diagnosed with bullous diseases over the observed time period. Oral prednisone was the primary treatment prescribed for patients with both bullous pemphigoid and pemphigus. Though prednisone is the primary medication prescribed for patients with blistering disorders, immunosuppressive therapies are associated with increased morbidity in elderly patients. Alternative therapies should be considered for the treatment of autoimmune bullous disorders when feasible taking into account the associated risks and side effect profile of these medications

show abstract

“…It has also been postulated that rituximab presents an additional effect on Dsg-3-specific, autoreactive CD4+ T helper cells, which are essential for the regulation of the autoimmune response in PV [13]. This dual effect of rituximab may be responsible of the remarkable clinical and serological improvement observed in most PV patients treated with this therapy to date [13,14,15,16,17,20]. …”

Section: Discussionmentioning

confidence: 99%

Rituximab in Childhood Pemphigus Vulgaris: A Long-Term Follow-Up Case and Review of the Literature

et al. 2010

View full text Add to dashboard Cite

Pemphigus vulgaris is an infrequent but life-threatening autoimmune blistering disease that is rare in the pediatric age. Although the mainstay of therapy for childhood pemphigus vulgaris (CPV) is steroids, adjuvant immunosuppressive drugs are often needed to control the disease. Thus, an important part of CPV morbidity can be related to treatment. We report the youngest CPV patient described in the English literature, an 18-month-old boy, who has been followed up for 16 years. During this period, the patient has received several immunosuppressive therapies with variable response. He has finally achieved a long-lasting and complete remission with rituximab. Successful treatment with rituximab has previously been reported in 6 cases of CPV, in whom rituximab presented a good side effect profile. Our patient has experienced a chronic and severe clinical course with multiple flares eventually developing vegetative lesions. Since he presented refractoriness to multiple therapies, we administered rituximab. The introduction of this drug led to a dramatic clinical response and a long-term clinical remission. Based on the experience of this case and the data reported in the literature, we believe that rituximab may be a safe and efficacious agent for the treatment of severe CPV.

show abstract

Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris

Cited by 62 publications

References 65 publications

Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression

Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression

Characterizing the Treatment of Autoimmune Bullous Disorders from 1993 through 2010: a NAMCS Study

Rituximab in Childhood Pemphigus Vulgaris: A Long-Term Follow-Up Case and Review of the Literature

Contact Info

Product

Resources

About